GLONGHUI November 15 | CITIC Lyon published a report stating that Alibaba Health's target price was raised by 14% from HK$5.6 to HK$6.4, maintaining the “buy” rating. CITIC Lyon predicts that Alibaba Health's total revenue for the first half of the year ending September 2023 will be 12.9 billion yuan, an increase of 12% over the previous year, and an adjusted net profit margin of 3.2%. Alibaba Health can use its large and growing base of merchants and stock level units (SKUs) to expand the price range and improve user retention. Furthermore, it is predicted that Alibaba Health's 15% growth target for the full year ending March 2024 is already on the right track. As the parent company shifts its goals back to Taobao, it may benefit from the parent company.